Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

U.S. Government Taps Glaxosmithkline Plc For New Antibiotics-Reuters


Wednesday, 22 May 2013 07:01am EDT 

Reuters reported that the U.S. government has signed an antibiotics development deal worth up to $200 million with GlaxoSmithKline to tackle the dual threats of drug resistance and bioterrorism. The collaboration, the first of kind between Washington and a drug company, will allow funding to move around GSK's antibiotics portfolio rather than focusing on a single drug candidate. The collaboration between GSK and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, will study potential new drugs to treat conventional pathogens and those that might be developed as bioterrorism weapons. Britain's drugmaker said on May 22, 2013, it would receive $40 million for an initial 18 months and up to a total of $200 million if the agreement is renewed over five years. 

Company Quote

53.71
-0.69 -1.27%
11 Jul 2014